Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has T2DM~* Has HbA1c between 6.5% (48 mmol/mol) and 8.0% (64 mmol/mol) on stable dose(s) of antihyperglycemic agent(s), including insulin~* Has pre-existing cardiovascular disease~Exclusion Criteria:~* Has a history of type 1 diabetes mellitus or ketoacidosis.~* Is not able to take sitagliptin

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).